C. Aubron-Olivier

发表

Switching the nucleoside reverse transcriptase inhibitor backbone to tenofovir disoproxil fumarate + emtricitabine promptly improves triglycerides and low-density lipoprotein cholesterol in dyslipidaemic patients.

C. Katlama, D. Costagliola, P. Giral, 2010, The Journal of antimicrobial chemotherapy.

Polylactic acid implants (New-Fill)® to correct facial lipoatrophy in HIV-infected patients: results of the open-label study VEGA

Philippe Katz, Christine Katlama, C. Katlama, 2003, AIDS.

Successful control of subfulminant hepatitis related to lamivudine-resistant hepatitis B virus in an HIV-infected patient.

D. Thabut, T. Poynard, B. Bernard, 2001, AIDS.

Primary infection with a lamivudine-resistant hepatitis B virus.

H. Agut, C. Katlama, V. Thibault, 2002, AIDS.

Discontinuation of maintenance therapy for cytomegalovirus retinitis in HIV-infected patients receiving highly active antiretroviral therapy

C. Tural, G. Carcelain, R. Tubiana, 2001, AIDS.

Management of chemotherapy-induced anemia (CIA) with biosimilar epoetin alfa (Binocrit) in patients with colorectal cancer (CC): An interim analysis of an ongoing French national observational study (The OncoBOS study).

J. Metges, G. Boschetti, O. Stamerra, 2015 .

Compliance with ASCO 2006 recommendations for the use of "white blood cell growth factors" in advanced lung cancer (LC) or breast cancer (BC) or non-Hodgkin lymphoma (NHL): An interim analysis of French National Observational Study—The ZOHé study.

C. Haioun, P. Solal-Céligny, H. Roché, 2014 .

Efficacy and safety of tenofovir double‐dose in treatment‐experienced HIV‐infected patients: The tenoplus study

V. Calvez, C. Katlama, G. Peytavin, 2007, Journal of medical virology.

Resistance profiles of emtricitabine and lamivudine in tenofovir-containing regimens.

V. Calvez, C. Charpentier, C. Katlama, 2012, The Journal of antimicrobial chemotherapy.